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Edited by Frances ShannonAbstract IL-4 plays a crucial role in the pathogenesis of aller-
gic diseases, such as the induction of IgE synthesis and the devel-
opment of mast cells. To further understand the eﬀect of IL-4 on
mast cells in skin, we utilized a mast cell/ﬁbroblast co-culture
system as an in vitro model of dermal mast cells. IL-4 induced
mast cell growth in the culture with ﬁbroblasts. Immunoblot
analysis revealed that IL-4 activated Stat6 in both mast cells
and ﬁbroblasts. The over-expression of dominant-negative Stat6
in ﬁbroblasts in the presence of IL-4 decreased the histamine
content per mast cell, but not the number of mast cells. In con-
trast, the over-expression of constitutively-active Stat6 in ﬁbro-
blasts increased the histamine content per mast cell, indicating
that the activation of Stat6 in ﬁbroblasts supports the maturation
of mast cells co-cultured with ﬁbroblasts.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Interleukin (IL)-4, a Th2 cytokine, is believed to play a cru-
cial role in the pathogenesis of allergic disorders, such as
allergic asthma and atopic dermatitis. IL-4 causes the switch
of immunoglobulin isotype produced by B cells from IgM to
IgE [1], and the development of mast cells, which provoke
immediate hypersensitivity reactions via the high aﬃnity
IgE receptors [2]. Moreover, the IL-4 expression in skin le-
sions of atopic dermatitis was signiﬁcantly higher than that
in non-aﬀected and normal skin in vivo [3]. The signaling
pathways triggered by IL-4 receptor engagement are medi-
ated through signal transfer and activator of transcription
(Stat)6 and phosphotyrosine binding domain-containing pro-Abbreviations: BMMC, bone marrow-derived mast cells; CTMC,
connective tissue mast cells; IL-4, interleukin-4; MCP-1, monocyte
chemotactic protein-1; MMC, mucosal mast cells; SCF, stem cell
factor; Stat6, signal transducer and activator of transcription 6; Stat6F,
dominant-negative Stat6; Stat6VT, constitutively-active Stat6
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doi:10.1016/j.febslet.2005.09.104teins [4,5]. Upon IL-4 stimulation, the monomeric Stat6 pro-
tein is recruited to the IL-4 receptor a-chain, and then
phosphorylated on tyrosine 641 by Janus kinase (Jak)1 and/
or Jak3. The phosphorylated Stat6 dimerizes, migrates to
the nucleus, binds to speciﬁc DNA elements, and activates
transcription of IL-4 responsive genes [6, and references cited
therein].
Mast cells derive from bone marrow hematopoietic stem
cells, which migrate into other tissues, including skin, and
complete their diﬀerentiation under the strong inﬂuence of
stem cell factor (SCF) in each tissue environment [7]. Previous
reports have shown that IL-4 acts as a cofactor that enhances
the proliferation of murine mast cells and their maturation,
including histamine content, in concert with SCF [8,9] or
IL-3 [10] in the absence of other cell types. However, in skin,
mast cells reside in close association with dermal ﬁbroblasts,
which also have IL-4 receptors [11,12] and proliferate in re-
sponse to IL-4 [13]. We previously reported that an IL-6 fam-
ily cytokine, leukemia inhibitory factor, enhances the growth
of mast cells when cultured with ﬁbroblasts, and that this ef-
fect was mediated by the Stat3 signaling pathway of ﬁbro-
blasts [14]. Further studies revealed that the release of SCF
from ﬁbroblasts was upregulated by the IL-6/Stat3 signaling
pathway in ﬁbroblasts (Hiragun et al., unpublished data).
Likewise, IL-4 may also aﬀect mast cells through the activa-
tion of ﬁbroblasts.
In this study, we investigated the eﬀect of IL-4 on the growth
and maturation of mast cells in a mast cell/ﬁbroblast co-cul-
ture system, as an in vitro model of dermal mast cells. This
study provides the ﬁrst evidence that ﬁbroblasts modulate
the maturation of co-existent mast cells by using the IL-4/Stat6
signaling pathway of the ﬁbroblasts.2. Materials and methods
2.1. Cells
Bone marrow-derived mast cells (BMMC) were prepared from 6-
week-old male mice (WBB6F1-+/+) according to the method de-
scribed previously [14]. Brieﬂy, bone marrow cells were cultured in
Minimum Essential Medium Alpha Medium (aMEM, Gibco BRL,
Rockville, MD) containing 10% fetal calf serum (FCS) and antibiotics
(complete aMEM), and supplemented with 100 lM 2-mercap-
toethanol and 5 ng/ml of recombinant murine interleukin-3 (rmIL-3,
R&D, Minneapolis, MN). After 4 weeks, more than 95% of the
non-adherent cells stained positively with alcian blue. NIH3T3 ﬁbro-
blasts (3T3 ﬁbroblasts) were obtained from The American Typeblished by Elsevier B.V. All rights reserved.
Fig. 1. IL-4 induces mast cell growth in the co-culture with ﬁbroblasts.
3 · 104 BMMC were seeded and cultured with 3T3 ﬁbroblasts in the
presence or absence of various concentrations of rmIL-4. Total
histamine content (A) and mast cell number (B) per well were
determined on day 6. Data are means ± S.E.M. of three independent
experiments done in triplicate (*P < 0.01).
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Modiﬁed Eagle Medium (DMEM, Gibco BRL) containing 10% calf
serum and antibiotics.
2.2. Co-culture of mast cells/3T3 ﬁbroblasts
Co-culture of BMMC/3T3 ﬁbroblasts was performed as described
previously [14]. Brieﬂy, 2 · 104 3T3 ﬁbroblasts suspended in 0.5 ml
of complete aMEM were seeded in each well of a four-well plate
(Nalge Nunc, Roskilde, Denmark), and then cultured until conﬂuent.
Upon reaching conﬂuency, 3 · 104 BMMC and various concentrations
of rmIL-4 (R&D) were added to the wells containing 3T3 ﬁbroblasts.
The culture medium was then changed every 2 days.
2.3. Mast cell counting in co-culture
Adherent cells in the co-cultures were dispersed by trypsin-EDTA
solution (Gibco BRL) for 10 min at 37 C, followed by the addition
of one tenth the volume of FCS. The dispersed cells were washed twice
with phosphate-buﬀered saline (PBS) and re-suspended in 1 ml of PBS
containing 1% bovine serum albumin. The total number of cells in the
suspension was determined by using an improved Neubauer haemocy-
tometer. Aliquots of cell suspensions were also spun in a cytocentri-
fuge (1500 rpm for 1 min) and the resulting cell preparations on
glass slides were stained with alcian blue. The alcian blue-positive cells
(mast cells) in a culture well were calculated using the following for-
mula: number of mast cells/well = A · C/B, where A is the total num-
ber of cells in a culture well, B is the total number of cells in a
cytocentrifuge specimen, and C is the number of alcian blue-positive
cells in the same specimen.
2.4. Determination of histamine content in co-culture
Cultured cells in each wells were denatured by the addition of 0.25 N
HClO4, and insoluble proteins were precipitated by centrifugation at
12000 · g at 4 C for 10 min. Histamine concentration was assayed
with an automated ﬂuorometric-HPLC system (Tosoh, Tokyo, Japan)
as described by Tsuruta et al. [15].
2.5. Western blot analysis
Cells were stimulated with rmIL-4 for the indicated periods and
lyzed with sample buﬀer (62.5 mM Tris–HCl (pH 6.8), 2% sodium
dodecyl sulfate, 10% glycerol, 50 mM DTT, and 0.1% bromophenol
blue). The cell lysates were subjected to electrophoresis by the method
of Laemmli [16] and separated on a 5–20% polyacrylamide gel (Atto,
Tokyo, Japan). The proteins were transferred to a polyvinylidene
diﬂuoride membrane (Immobilon-P, Millipore, Bedford, MA). The
membrane was incubated with rabbit anti-phospho-Stat6 antibody
that recognizes phosphorylated Stat6 on tyrosine 641 (Cell signaling
technology, Beverly, MA) or anti-Stat6 antibody (Calbiochem, San
Diego, CA). After washing with Tris–buﬀered saline with Tween-20,
the membranes were incubated with horseradish peroxidase (HRP)-
conjugated anti-rabbit IgG antibody. The reacted antibodies were
visualized by using ECL (Amersham Pharmacia Biotech, Buckingham-
shire, UK) under a luminescent image analyzer (LAS-1000 plus, Fuji
Photo Film, Tokyo, Japan).
2.6. Stat6 expression vectors
Total RNA was extracted from NIH3T3 ﬁbroblasts and converted
to single-stranded cDNA by the use of Supercript II (Invitrogen,
Carlsbad, CA). The double-stranded cDNA encoding mouse
Stat6 was ampliﬁed by RT-PCR using the sense primer (5 0-
TGCTCTAGACGCTGGACAGACCTACAGACC-30) and the
antisense primer (5 0-TGCTCTAGAAGCAGGTGTCCAGAGCT-
GGTC-30). The PCR product was digested with XbaI and ligated into
the XbaI sites of pEF-BOS (a gift from Dr. Nagata, Department of
Genetics, Osaka University Medical School, Osaka, Japan) or
pME18S (a gift from Dr. Kitamura, Divisions of Cellular Therapy,
The Institute of Medical Science, The University of Tokyo, Tokyo, Ja-
pan). The mutagenesis of constitutively-active (V547A/T548A) [17]
and dominant-negative (Y641F) [18] Stat6 was performed by the
QuikChangeR Site Directed Mutagenesis Kit (Stratagene, La Jolla,
CA) with the primer pairs for constitutively-active Stat6 (Stat6VT):
5 0-GCTTTATTAGTAAGCAATATGCCGCTAGCCTTCTCCTCA-
ATGAGC-30 and 5 0-GCTCATTGAGGAGGAGGCTAGCGGCA-
TATTGCTTACTAATAAAGC-3 0; or the primer pairs for domi-nant-negative Stat6 (Stat6F): 5 0-GGGAAGGACGGGAG-
GGGTTTTGTCTCTACTACTATCAAG-3 0 and 5 0-CTTGATAG-
TAGTAGAGACAAAACCCCTCCCGTCCTTCCC-3 0.
2.7. Transfection
All plasmids for transfection were puriﬁed with the EndoFreeR Plas-
mid Puriﬁcation Kit (Qiagen, Hilden, Germany). 3T3 ﬁbroblasts were
transfected with the vector alone (mock), wild-type Stat6, Stat6VT, or
Stat6F by electroporation as previously described [14]. 3T3 ﬁbroblasts,
which were co-transfected with pEF-Stat6F and pSV2neo, were se-
lected with 1 mg/ml of G418 for two weeks. The stably transfected
clone that exhibited the highest exogenous Stat6 was selected by immu-
noblotting using anti-Stat6 antibody (Calbiochem), and then utilized
for further experiments.
2.8. ELISA
The concentrations of SCF and MCP-1 in the culture supernatants
of 3T3 ﬁbroblasts were determined by using the SCF ELISA Kit
(R&D) and the MCP-1 ELISA Kit (Biosource International, Cama-
rillo, CA) according to the manufacturers instructions.
2.9. Cytokine antibody array
The mock- and Stat6F-transfected ﬁbroblasts were cultured in the
presence or absence of 100 ng/ml of rmIL-4 for 12 h, and then the cul-
ture supernatants were collected. Cytokines in the supernatants were
detected with Cytokine Antibody Array III (RayBiotech, Norcross,
GA) according to the manufacturers instructions.3. Results
3.1. IL-4 enhances mast cell growth in co-culture
The eﬀect of IL-4 on mast cells co-cultured with ﬁbroblasts
was examined, by measuring the amount of histamine and the
number of mast cells. IL-4 increased both histamine content
(Fig. 1A) and mast cell number (Fig. 1B) simultaneously in a
dose-dependent manner. The parallel increase of the two
parameters indicated that the histamine content per mast cell
was constant (approximately 0.4 pg/cell).
3.2. IL-4 activates Stat6 in both BMMC and 3T3 ﬁbroblasts
To determine whether IL-4 aﬀects BMMC, 3T3 ﬁbroblasts,
or both, the activation of Stat6, the dominant downstream sig-
naling molecule of the IL-4 receptor, was investigated. Western
blot analysis revealed that the phosphorylation of Stat6 on
tyrosine 641 in BMMC was apparent 1 min after the addition
of IL-4, being enhanced until 5 min (Fig. 2, upper panel), and
Fig. 2. IL-4 activates Stat6 in both BMMC and 3T3 ﬁbroblasts.
BMMC and 3T3 ﬁbroblasts were stimulated with 100 ng/ml of rmIL-4
for the indicated periods and then lyzed. Control cells were not
stimulated with rmIL-4. Immunoblots were prepared from whole cell
lysates by the use of antibodies that recognized phosphorylated Stat6
(anti-P-Stat6) or total Stat6 (anti-Stat6). A representative immunoblot
from three experiments is shown.
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of Stat6 in 3T3 ﬁbroblasts had a relatively slow onset (at
5 min) and further increased until 30 min (Fig. 2, lower panel).
3.3. Disruption of the IL-4/Stat6 signaling pathway of
ﬁbroblasts decreases the histamine content of mast cells
To determine the role of Stat6 activation of ﬁbroblasts in the
mast cell/ﬁbroblast co-culture system, a ﬁbroblast clone that
expressed dominant-negative Stat6 (Stat6F) was established.
The exogenous expression of Stat6F blocked the IL-4-induced
activation of endogenous Stat6 in 3T3 ﬁbroblasts (Fig. 3A).
The blockade of Stat6 activation in 3T3 ﬁbroblasts impaired the
increase of total histamine content (Fig. 3B), but enhanced
the increase of mast cell numbers (Fig. 3C), resulting in a
markedly lower (approximately 40%) histamine content per
mast cell (Fig. 3D). These results indicated that the disruption
of the IL-4/Stat6 signaling pathway of 3T3 ﬁbroblasts
decreases the histamine content per mast cell.Fig. 3. Disruption of the IL-4/Stat6 signaling pathway of ﬁbroblasts decreas
which were stably transfected with vector alone (mock) or dominant-negativ
and then lyzed. Control ﬁbroblasts were not stimulated with rmIL-4. Immun
that recognized phosphorylated or total Stat6. A representative immunoblot
and cultured with mock- or Stat6F-transfected ﬁbroblasts in the presence or
cell numbers (C), and calculated histamine content per mast cell (D) were
experiments done in triplicate (*P < 0.01).3.4. Activation of Stat6 in 3T3 ﬁbroblasts increases the
histamine content of mast cells
The eﬀect of Stat6 activation in 3T3 ﬁbroblasts on the hista-
mine content of mast cells was further validated by experiments
with 3T3 ﬁbroblasts expressing constitutively-active Stat6
(Stat6VT). Similar to a previous study [17], Western blot anal-
ysis demonstrated that the Stat6VT protein was tyrosine-phos-
phorylated independent of IL-4 (Fig. 4A). The co-culture of
mast cells with transfected 3T3 ﬁbroblasts revealed that the acti-
vation of Stat6 solely in 3T3 ﬁbroblasts induced a marked in-
crease of total histamine content (Fig. 4B), and a moderate
increase of mast cell number (Fig. 4C), resulting in a twofold in-
crease of histamine content per mast cell (Fig. 4D).
3.5. IL-4 does not increase the release of SCF from 3T3
ﬁbroblasts
Stem cell factor (SCF) is expressed and released by stromal
cells including ﬁbroblasts, and is known to act for both the
growth and the diﬀerentiation of mast cells [7]. To study
whether SCF is involved in the eﬀect of IL-4 on mast cells in
our system, we examined the eﬀect of IL-4 on the release of
SCF from 3T3 ﬁbroblasts. The ELISA assay revealed that
the amount of SCF released from either mock- or Stat6F-
transfected ﬁbroblasts was not aﬀected by up to 100 ng/ml of
IL-4, whereas signiﬁcantly enhanced by IL-6 regardless of
the cell types (Fig. 5).4. Discussion
We have demonstrated that IL-4 increases the histamine con-
tent of mast cells via the Stat6 signaling pathway of ﬁbroblasts
in the mast cell/ﬁbroblast co-culture system. Disruption of the
IL-4/Stat6 signaling pathway of ﬁbroblasts by over-expression
of Stat6F dramatically decreased the histamine content per
mast cell, but not the number of mast cells. The complementary
experiments using Stat6VT showed that Stat6VT increased thees the histamine content of co-cultured mast cells. (A) 3T3 ﬁbroblasts,
e Stat6 (Stat6F), were stimulated with 100 ng/ml of rmIL-4 for 5 min,
oblots were prepared from whole cell lysates by the use of antibodies
from three experiments is shown. (B–D) 3 · 104 BMMC were seeded
absence of 100 ng/ml of rmIL-4. The total histamine content (B), mast
determined on day 6. Data are means ± S.E.M. of three independent
Fig. 4. Activation of Stat6 in 3T3 ﬁbroblasts increases the histamine content of mast cells. (A) 3T3 ﬁbroblasts were transiently transfected with
vector alone (mock), wild-type Stat6 (Stat6WT), or constitutively-active Stat6 (Stat6VT), incubated overnight, and then lyzed. Immunoblots were
prepared from whole cell lysates by the use of antibodies that recognized phosphorylated Stat6 or total Stat6. A representative immunoblot from
three experiments is shown. (B–D) 3 · 104 BMMC were seeded and cultured with mock- or Stat6VT-transfected ﬁbroblasts. The total histamine
content (B), mast cell numbers (C), and calculated histamine content per mast cell (D) were determined on day 6. Data are means ± S.E.M. of three
independent experiments done in triplicate (*P < 0.05).
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results indicated that the activation of Stat6 in 3T3 ﬁbroblasts
is necessary to keep histamine content high during IL-4-in-
duced proliferation of mast cells.
Histamine is preformed and stored in the cytoplasmic gran-
ules of mast cells, released by the crosslinking of the high aﬃn-
ity IgE receptors or other stimuli, and causes urticaria,
anaphylaxis, and/or other symptoms observed in atopic dis-
eases [19]. There are two distinct populations of mast cells in
mice, connective tissue mast cells (CTMC) and mucosal mast
cells (MMC). BMMC developed by IL-3 are relatively imma-
ture and resemble MMC. By co-culturing with ﬁbroblasts and/
or the treatment with SCF, BMMC diﬀerentiate to CTMC.
These are characterized by higher histamine content than
MMC [20], the diﬀerential expression proﬁle of mast cell pro-Fig. 5. IL-4 does not enhance the release of SCF from 3T3 ﬁbroblasts.
Mock- and Stat6F-transfected ﬁbroblasts were treated with various
concentrations of rmIL-4 or 100 ng/ml of IL-6 for 3 days. Control cells
were cultured without rmIL-4 or IL-6. The culture supernatants were
collected and the amount of SCF in the supernatant was determined by
a murine SCF ELISA kit. Data are means ± S.E.M. of three
independent experiments done in triplicate (*P < 0.01).teases [21], and possession of reactivity to compound 48/80 and
substance P [22]. Thus ﬁbroblasts and ﬁbroblast-derived cyto-
kine, SCF, play a key role in the diﬀerentiation of mast cells.
However, unlike IL-6, IL-4 did not increase the release of
SCF from ﬁbroblasts, indicating that other factor(s) are dom-
inantly involved in the ﬁbroblast-mediated maturation of mast
cells in the presence of IL-4. We utilized the cytokine antibody
array to investigate the expression proﬁle of cytokines induced
by the activation of IL-4/Stat6 signaling pathway of ﬁbro-
blasts. Amongst 62 cytokines on the array, monocyte chemo-
tactic protein-1 (MCP-1) was upregulated in the ﬁbroblasts
with the mock-transfection, but not those with dominant-
negative form Stat6, in the presence of IL-4 (Fig. 6A). The
upregulation of MCP-1 was conﬁrmed by means of an ELISA
assay (Fig. 6B), suggesting the role of MCP-1 in the synthesis
of histamine. In fact, it has been reported that MCP-1
increased the mRNA of histidine decarboxylase, the essential
enzyme that synthesizes histamine from histidine [23], in rat
peritoneal mast cells [24]. However, the neutralizing antibodies
against MCP-1 did not inhibit the increase of histamine of the
mast cells co-cultured with Stat6VT-expressing 3T3 ﬁbroblasts
(data not shown). Therefore, the contribution of MCP-1 to the
ﬁbroblast-induced maturation of mast cells should be small or
not essentially required. Other unidentiﬁed cytokines and/or
membranous molecules produced by ﬁbroblasts are expected
to be identiﬁed by further studies of IL-4 and Stat6.
The IL-4 receptor consists of IL-4 receptor a and gamma
common chain (cc), and the latter can be replaced by IL-13
receptor a (type II IL-4 receptor) [6]. IL-13 can bind the type
II IL-4 receptor, act through the same downstream signaling
molecule, Stat6, and thus elicit similar biological responses
associated with allergic disorders [25]. Both mast cells [26]
and ﬁbroblasts [27] have been reported to express the IL-13
receptor a subunit, suggesting the potential role of IL-13 is
similar to IL-4 on dermal mast cells.
In conclusion, we have shown that the maturation of mast
cells is regulated by the IL-4/Stat6 signaling pathway of
Fig. 6. IL-4 increases the release of MCP-1 from 3T3 ﬁbroblasts by
Stat6 signaling pathway. 3T3 ﬁbroblasts, which were stably transfected
with vector alone (mock) or dominant-negative Stat6 (Stat6F), were
stimulated with 100 ng/ml of rmIL-4 for 12 h (A) or 36 h (B). Control
ﬁbroblasts were not treated with IL-4. (A) The culture supernatants
were collected and analyzed by the cytokine antibody array. The black
and white arrowheads indicate the spots corresponding to IL-4 and
MCP-1 on each membrane, respectively. (B) The amount of MCP-1 in
the culture supernatants were determined by a mouse MCP-1 ELISA
kit. Data are means ± S.E.M. of three independent experiments done
in triplicate (*P < 0.01).
Y. Nabeshima et al. / FEBS Letters 579 (2005) 6653–6658 6657ﬁbroblasts, separately from their proliferation, in the mast cell/
ﬁbroblast co-existent system. Our study provides new insight
into the interaction between mast cells and ﬁbroblasts in con-
nective tissues, and suggests that Stat6 in dermal ﬁbroblasts is
a possible therapeutic target in allergic skin diseases.
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